What are the next medication options for depression if Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Monoamine Oxidase Inhibitors (MAOIs) have been tried?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 6, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medication Options for Treatment-Resistant Depression

When SSRIs, SNRIs, and MAOIs have failed to treat depression, atypical antidepressants (bupropion, mirtazapine), second-generation antipsychotics (quetiapine, aripiprazole), or anticonvulsants should be considered as the next treatment options, with bupropion being the preferred first choice due to its favorable side effect profile and efficacy. 1

Atypical Antidepressants

Bupropion

  • Mechanism: Predominantly norepinephrine and dopamine reuptake inhibitor
  • Advantages:
    • Different mechanism of action from previously tried medications
    • Lower rates of sexual dysfunction compared to SSRIs/SNRIs
    • No significant weight gain
    • Shown to be effective in the STAR*D trial for patients who failed initial SSRI therapy 2
  • Dosing: Starting at 150mg daily, target dose 300-450mg daily
  • Contraindications: Seizure disorders, eating disorders, abrupt discontinuation of alcohol or sedatives

Mirtazapine (NaSSA)

  • Mechanism: Noradrenergic and specific serotonergic antidepressant
  • Advantages:
    • Faster onset of action than SSRIs (statistically significant in first 4 weeks) 2
    • Helpful for patients with insomnia and poor appetite
    • Different side effect profile than SSRIs/SNRIs
  • Dosing: Starting at 15mg at bedtime, target dose 30-45mg
  • Side effects: Sedation, increased appetite, weight gain

Augmentation Strategies

Second-Generation Antipsychotics

  • Options: Quetiapine, aripiprazole, olanzapine
  • Evidence:
    • Effective as monotherapy or as augmentation to SSRIs in treatment-resistant cases 3
    • Quetiapine has demonstrated efficacy in major depressive disorder 4
  • Dosing:
    • Quetiapine: 50-300mg daily (lower doses than used for psychotic disorders)
    • Aripiprazole: 2-15mg daily
  • Monitoring: Metabolic parameters (weight, glucose, lipids), extrapyramidal symptoms

Anticonvulsants

  • Options: Lamotrigine, valproic acid, topiramate
  • Particularly useful when:
    • Comorbid bipolar features are present
    • Impulsivity and anger are prominent symptoms 3
  • Lamotrigine has shown efficacy in small controlled studies 3
  • Requires careful titration and monitoring of blood levels (for valproic acid)

Other Considerations

Tricyclic Antidepressants (TCAs)

  • Options: Clomipramine, imipramine, desipramine
  • More effective than SSRIs for some patients, but with higher side effect burden 2
  • Should be considered third-line due to:
    • Cardiovascular side effects
    • Anticholinergic effects
    • Risk in overdose
    • Drug interactions

Transdermal Selegiline (MAO-B Inhibitor)

  • If traditional MAOIs failed but were partially effective, consider transdermal selegiline
  • Advantages over traditional MAOIs:
    • Selective MAO-B inhibition at lower doses
    • Fewer dietary restrictions
    • Lower risk of hypertensive crisis 5
  • Still requires careful monitoring and medication interaction precautions

Combination Therapy

In cases of severe treatment resistance, carefully monitored combination therapy may be considered:

  • Combination of an MAOI with another antidepressant showed 21% significant improvement in treatment-resistant cases 6
  • CAUTION: This approach carries significant risks of serotonin syndrome and should only be implemented by psychiatrists with expertise in managing treatment-resistant depression

Important Considerations

  1. Suicide Risk Assessment: Closely monitor for suicidal ideation, especially in patients under 24 years of age 4, 7

  2. Medication Selection Algorithm:

    • First attempt: Bupropion (different mechanism of action)
    • If ineffective: Try mirtazapine
    • If still ineffective: Consider augmentation with second-generation antipsychotic
    • If still ineffective: Consider anticonvulsants or TCA
    • Last resort: Carefully monitored combination therapy

  3. Duration of Treatment:

    • Continue effective treatment for at least 12-24 months after achieving remission 1
    • Taper medications slowly when discontinuing to avoid withdrawal effects

  4. Common Pitfalls:

    • Inadequate dosing or duration before switching medications
    • Failure to monitor for side effects that may reduce adherence
    • Not addressing comorbid conditions (anxiety, substance use) that may affect treatment response
    • Overlooking drug interactions that may reduce efficacy

Remember that treatment-resistant depression often requires a comprehensive approach. Each medication trial should be given adequate time (6-8 weeks) at therapeutic doses before determining efficacy, while carefully monitoring for side effects and treatment response.

References

1
Guideline

Treatment of Depression and Related Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

5
Research

Translating the evidence on atypical depression into clinical practice.

The Journal of clinical psychiatry, 2007

Related Questions

Are Selective Serotonin Reuptake Inhibitors (SSRIs) effective for treating mental health conditions based on studies newer than 2020?
If a Selective Serotonin Reuptake Inhibitor (SSRI) is not effective at its maximum dose, should I try a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)?
What is the next best treatment option for a 16-year-old patient with worsening depression and anxiety who has failed all Selective Serotonin Reuptake Inhibitors (SSRIs)?
What is the next best step for a patient with treatment-resistant depression and anxiety who has failed multiple Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and is currently not responding to Viibryd (vilazodone)?
What is the recommended time of day for taking various antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), and Monoamine Oxidase Inhibitors (MAOIs), in an adult patient with a history of depression or anxiety?
What is the management for a 45-year-old male with a blood lead level of 4.7 micrograms per deciliter (μg/dL)?
What are the diagnosis and treatment options for Polycystic Ovary Syndrome (PCOS)?
What is the treatment for folliculitis barbae?
What is the best approach to manage recurrent urinary tract infections?
What are the symptoms of hypercalcemia?
What are the next steps for managing chronic back pain that has not responded to Duloxetine, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (APAP), steroid shots, and physical therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question